• Publications
  • Influence
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.
TLDR
RIC and haplo-cord transplantation results in fast engraftment of neutrophils and platelets, low incidences of aGVHD and cGVHD, low frequency of delayed opportunistic infections, reduced transfusion requirements, shortened length of hospital stay, and promising long-term outcomes.
Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis.
TLDR
SB1518 shows promising efficacy in symptomatic MF patients with splenomegaly, with manageable GI toxicity as the main side effect, and patients with significantly impaired hematopoiesis can receive full-dose daily SB1518 without exacerbating hematocytopenias.
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes
TLDR
Clofarabine used as a bridge to HCT reduces disease burden, is well tolerated, and permits high-risk patients to undergo HCT with acceptable NRM, comparing favorably to published data for high- risk patients.
Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia
TLDR
No evaluable patients experienced a complete remission (CR) or CR with incomplete blood count recovery (CRi), demonstrating no evidence of AZD4877 efficacy in this population, and this study was terminated due to lack of efficacy.
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
TLDR
A ⩾50% reduction in palpable spleen size was achieved in 56% of patients (47%) of patients with prior JAKi treatment, and improvements were observed in myelofibrosis-associated symptoms, and NS-018 reached peak plasma concentration in 1–2 h and did not accumulate with multiple dosing.
Reduced intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engrafment and durable remissions.
TLDR
Combined haploidentical donor and UCB transplantation in the large majority of patients results in rapid neutrophil engraftment due to the haplo-identical progenitor cells, even in patients with active disease at transplant.
Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?
TLDR
In order to address some of the principal challenges, an expert panel of laboratory and clinical experts in this field was established, and an independent workshop held, and this document summarizes the results of these efforts.
Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies.
TLDR
A phase I study to establish the DLT and maximally tolerated dose (MTD) of XK469R in patients with refractory hematologic malignancies, as well as to study the pharmacokinetics of the drug in this patient population.
Targeting multiple signal pathways simultaneously might provide effective therapeutic strategies in acute myeloid leukemia.
TLDR
The authors' data provide a strong rationale for combinational targeting of PI3K/Akt/mTOR and MEK pathways for the treatment of AML and suggest that inhibition of BCl-2 family members by ABT263 may provide additional therapeutic benefit.
A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies.
TLDR
The combination of BEL and AZC is feasible, responses have been observed in several pts at the RP2D of 1000mg/m2 of BEL plus 75mg/ m2 AZC, suggesting a relative biologic contribution of BEL to the combination.
...
1
2
...